Scientists decode myeloma DNA to personalize future treatments
NCT ID NCT06338150
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 31 times
Summary
This study will analyze the genetic makeup of tumors from 100 people with relapsed multiple myeloma. Researchers will use advanced DNA and RNA sequencing to find genetic changes and understand how the cancer works. The goal is to gather information that could guide more personalized treatment choices in the future. Participants will provide blood, cheek swab, and tumor samples during routine care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Mount Sinai Health System
RECRUITINGNew York, New York, 10029, United States
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors better understand the genetic makeup of multiple myeloma and point toward more personalized treatment options.
What could go wrong
This is an early-stage observational study, not a treatment trial. It is not designed to test whether any specific therapy works, so results may not directly benefit participants.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.